S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NYSE:SNY

Sanofi - SNY Stock Forecast, Price & News

$38.02
+0.02 (+0.05%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$38.01
$38.58
50-Day Range
N/A
52-Week Range
$36.91
$58.10
Volume
2.93 million shs
Average Volume
2.48 million shs
Market Capitalization
$96.38 billion
P/E Ratio
N/A
Dividend Yield
3.32%
Price Target
N/A
SNY stock logo

About Sanofi (NYSE:SNY) Stock

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Stock News Headlines

See More Headlines
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers—General
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Outstanding Shares
2,534,960,000
Free Float
N/A
Market Cap
$96.38 billion
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Paul Hudson (Age 55)
    CEO & Director
    Comp: $5.64M
  • Mr. Jean-Baptiste Chasseloup de Chatillon (Age 57)
    Exec. VP & CFO
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard
    Chief Information officer
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 44)
    Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 65)
    Sr. VP of Global Diabetes and Sr. VP of Global Marketing













SNY Stock - Frequently Asked Questions

How have SNY shares performed in 2022?

Sanofi's stock was trading at $50.0111 at the beginning of the year. Since then, SNY shares have decreased by 24.0% and is now trading at $38.02.
View the best growth stocks for 2022 here
.

Is Sanofi a good dividend stock?

Sanofi (NYSE:SNY) pays an annual dividend of $1.26 per share and currently has a dividend yield of 3.32%.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Pfizer (PFE), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), AbbVie (ABBV), AT&T (T) and Alibaba Group (BABA).

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $38.02.

How much money does Sanofi make?

Sanofi (NYSE:SNY) has a market capitalization of $96.38 billion.

How can I contact Sanofi?

The official website for the company is www.sanofi.com. The company can be reached via phone at 33 1 53 77 40 00.

This page (NYSE:SNY) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.